251 related articles for article (PubMed ID: 29246530)
1. Controversies in rheumatoid arthritis glucocorticoid therapy.
Ruyssen-Witrand A; Constantin A
Joint Bone Spine; 2018 Jul; 85(4):417-422. PubMed ID: 29246530
[TBL] [Abstract][Full Text] [Related]
2. DMARD use in early rheumatoid arthritis. Lessons from observations in patients with established disease.
Aletaha D; Smolen JS
Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S169-73. PubMed ID: 14969071
[TBL] [Abstract][Full Text] [Related]
3. The Utrecht experience with different treatment strategies in early rheumatoid arthritis.
Verstappen SM; Jacobs JW; Bijlsma JW;
Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S165-8. PubMed ID: 14969070
[TBL] [Abstract][Full Text] [Related]
4. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).
Hørslev-Petersen K; Hetland ML; Ørnbjerg LM; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
Ann Rheum Dis; 2016 Sep; 75(9):1645-53. PubMed ID: 26489704
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA.
Stouten V; Westhovens R; Pazmino S; De Cock D; Van der Elst K; Joly J; Verschueren P;
Rheumatology (Oxford); 2019 Dec; 58(12):2284-2294. PubMed ID: 31236568
[TBL] [Abstract][Full Text] [Related]
7. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
[TBL] [Abstract][Full Text] [Related]
8. The role of low-dose glucocorticoids for rheumatoid arthritis in the biologic era.
Caporali R; Scirè CA; Todoerti M; Montecucco C
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S9-13. PubMed ID: 24129129
[TBL] [Abstract][Full Text] [Related]
9. The CIMESTRA study: intra-articular glucocorticosteroids and synthetic DMARDs in a treat-to-target strategy in early rheumatoid arhtritis.
Hetland ML; Hørslev-Petersen K
Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S44-9. PubMed ID: 23079125
[TBL] [Abstract][Full Text] [Related]
10. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis.
Hoes JN; Jacobs JW; Buttgereit F; Bijlsma JW
Nat Rev Rheumatol; 2010 Dec; 6(12):693-702. PubMed ID: 21119718
[TBL] [Abstract][Full Text] [Related]
11. Databases of patients with early rheumatoid arthritis in the USA.
Sokka T; Willoughby J; Yazici Y; Pincus T
Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S146-53. PubMed ID: 14969067
[TBL] [Abstract][Full Text] [Related]
12. What is the best treatment strategy for early RA?
Leirisalo-Repo M
Best Pract Res Clin Rheumatol; 2013 Aug; 27(4):523-36. PubMed ID: 24315052
[TBL] [Abstract][Full Text] [Related]
13. Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review.
Kuijper TM; Lamers-Karnebeek FB; Jacobs JW; Hazes JM; Luime JJ
J Rheumatol; 2015 Nov; 42(11):2012-22. PubMed ID: 26428204
[TBL] [Abstract][Full Text] [Related]
14. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC
Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
[TBL] [Abstract][Full Text] [Related]
15. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
Svensson B; Boonen A; Albertsson K; van der Heijde D; Keller C; Hafström I
Arthritis Rheum; 2005 Nov; 52(11):3360-70. PubMed ID: 16255010
[TBL] [Abstract][Full Text] [Related]
16. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study.
Hetland ML; Stengaard-Pedersen K; Junker P; Lottenburger T; Hansen I; Andersen LS; Tarp U; Svendsen A; Pedersen JK; Skjødt H; Lauridsen UB; Ellingsen T; Hansen GV; Lindegaard H; Vestergaard A; Jurik AG; Østergaard M; Hørslev-Petersen K;
Ann Rheum Dis; 2008 Jun; 67(6):815-22. PubMed ID: 17878209
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic strategies in rheumatoid arthritis over a 40-year period.
Kremers HM; Nicola P; Crowson CS; O'Fallon WM; Gabriel SE
J Rheumatol; 2004 Dec; 31(12):2366-73. PubMed ID: 15570636
[TBL] [Abstract][Full Text] [Related]
19. Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM).
Mueller RB; Reshiti N; Kaegi T; Finckh A; Haile SR; Schulze-Koops H; Schiff M; Spaeth M; von Kempis J;
Clin Rheumatol; 2017 Jan; 36(1):59-66. PubMed ID: 27838788
[TBL] [Abstract][Full Text] [Related]
20. Better clinical outcome of total knee arthroplasty for rheumatoid arthritis with perioperative glucocorticoids and disease-modifying anti-rheumatic drugs after an average of 11.4-year follow-up.
Ren Y; Yang Q; Luo T; Lin J; Jin J; Qian W; Weng X; Feng B
J Orthop Surg Res; 2021 Jan; 16(1):84. PubMed ID: 33504345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
